Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities:
Net loss	$ (11,341)	$ (3,755)
Items not involving cash:
Depreciation	79	150
Amortization of discount on term loan	125	72
Deferred income tax (recovery) expense	33	(37)
Stock-based compensation	491	663
Unrealized foreign exchange (gain) loss	(23)	267
Gain on termination of collaboration agreement (note 9c)		(4,398)
Changes in operating assets and liabilities:
Accounts receivable	20	40
Prepaid expenses, and other current assets	389	(435)
Prepaid expenses, long term		230
Accounts payable and accrued expenses	1,560	(1,016)
Net cash used in operating activities	(8,667)	(8,219)
Investing activities:
Purchases of property, plant and equipment	(335)	(181)
Purchase of marketable securities	(34,325)	(8,148)
Proceeds from marketable securities	27,628	13,306
Net cash provided by (used in) investing activities	(7,032)	4,977
Financing activities:
Issuance of common shares pursuant to exercise of stock options	58	119
Net cash provided by financing activities	58	119
Effect of exchange rate changes on cash and cash equivalents	67	(163)
Decrease in cash and cash equivalents	(15,574)	(3,286)
Cash and cash equivalents, beginning of period	67,754	20,486
Cash and cash equivalents, end of period	52,180	17,200
Supplemental disclosures:
Interest paid	230	71
Interest received	709	141
Cash paid for operating lease	158	152
Supplemental disclosures of non-cash transactions:
Fair value of stock options exercised on a cashless basis	$ 7	176
Issuance of preferred shares in exchange for common shares (note 9b)		21,825
Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]
Supplemental disclosures of non-cash transactions:
Termination of Teva agreement through cancellation of common shares (note 9c)		$ 4,470